Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

Mechanistic Study of SPARC-Mediated Regulation of Neutrophil Extracellular Trap Formation in the Brain Metastatic Microenvironment of Breast Cancer

NCT07185646 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2023-01-01
Last updated
2025-09-23

Condition(s) studied

Neuro-OncologyMRI ImagingTumor Immune Microenvironment

Study summary

The objective of this observational study is to investigate the characteristics of the tumor microenvironment in patients with brain tumors using multi-modal magnetic resonance imaging (MRI). The primary research question it aims to address is:

• Can multi-modal MRI effectively characterize features of the immune microenvironment in brain tumor patients?

Participants:

Eligible participants who have been diagnosed with a brain tumor will undergo multi-modal MRI scans for detailed assessment of tumor microenvironment features.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. conventional MRI revealed intracranial space-occupying lesions and suspected high-grade gliomas, brain metastases and meningiomas; 2. It is planned to perform a brain tumor resection surgery in this institution. Exclusion Criteria: 1. other CNS diseases in addition to brain tumors; 2. pathologically confirmed brain tumors not belonging to any of the three selected types; 3. contraindications to the use of gadolinium contrast, including hypersensitivity to contrast agents, renal dysfunction, pregnancy or lactation; 4. contraindications to MRI; 5. poor image quality unsuitable for subsequent analyses; 6. age younger than 18 years.

Primary outcome measure(s)

  • Postoperative Progression-Free Survival — 6months,12months,24months
    Postoperative Progression-Free Survival is defined as the time interval from the date of surgical intervention until the first occurrence of either documented disease progression or death from any cause

Trial sites (1)

FacilityCityRegionStatus
the Second Xiangya Hospital of Central South University Changsha Hunan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07185646 on ClinicalTrials.gov ↗ ← All trials in China